How to Get Wegovy for Free in 2026: Every Real Path, With Eligibility Rules

Key Takeaways

• The Novo Nordisk Patient Assistance Program (NovoCare PAP) provides free Wegovy for qualifying low-income patients without insurance coverage.
• The Wegovy savings card reduces commercial-insurance copays to as little as $0 per month for eligible patients, but it is not the same as free.
• Medicare and Medicaid patients are excluded from manufacturer copay cards by federal law.
• Active clinical trials sometimes provide free GLP-1 medication plus stipends, but enrollment is competitive.
• Most "free Wegovy" offers from social-media ads or unverified websites are scams or counterfeit drug schemes.
• Compounded semaglutide is not free, but starts at $179 per month at FormBlends, often less than a typical Wegovy copay.

Direct answer (40-60 words)

The only legal way to get brand-name Wegovy at zero cost is through the Novo Nordisk Patient Assistance Program (NovoCare PAP) for income-qualified patients without insurance, or through enrollment in an active clinical trial. The Wegovy savings card can lower commercial-insurance copays, but it does not make the drug free for most patients.

Table of contents

1. The 30-second answer
2. The Novo Nordisk Patient Assistance Program (NovoCare PAP)
3. The Wegovy savings card and how close to "free" it can get
4. Clinical trials with free GLP-1 medication
5. State and nonprofit assistance programs
6. Why "free Wegovy" ads online are almost always scams
7. The compounded semaglutide alternative when free is not available
8. A 5-step plan to find your lowest-cost option
9. FAQ
10. Sources
11. Footer disclaimers

The Novo Nordisk Patient Assistance Program (NovoCare PAP)

The Novo Nordisk Patient Assistance Program is the manufacturer's safety-net program for patients who cannot afford Wegovy and have no insurance coverage for it. It provides the medication at no cost.

Eligibility (current as of 2026):

• Household income at or below 400% of the federal poverty level (about $60,240 for an individual or $124,800 for a family of four).
• Permanent U.S. resident.
• No prescription drug coverage, or coverage that explicitly excludes Wegovy.
• A licensed provider has determined Wegovy is medically necessary for chronic weight management.
• Patient is not enrolled in Medicare, Medicaid, TRICARE, VA, or another government-funded program. Medicare patients in particular have a separate Extra Help process.

What the program provides:

• Free Wegovy shipped directly from Novo Nordisk to the patient's address or to the prescribing clinic.
• Approval is typically valid for 12 months, renewable annually.
• Standard titration doses are included (0.25 mg starter through 2.4 mg maintenance).

How to apply:

1. The patient and provider download the application from the NovoCare website.
2. The provider completes the medical-necessity portion and signs.
3. The patient completes the income-verification portion (recent tax return or proof of income).
4. Application is mailed or faxed to NovoCare.
5. Approval typically arrives in 5 to 10 business days.

The PAP is the most under-used free-drug pathway in obesity medicine. Many providers do not routinely mention it because the paperwork burden lives on the provider side. Patients who suspect they may qualify should ask the prescribing clinic directly.

If a patient gains insurance coverage during the 12-month approval period, the PAP coverage usually ends and the patient transitions to insurance plus the savings card.

The Wegovy savings card and how close to "free" it can get

The Wegovy savings card (sometimes called the manufacturer copay card) is a separate program from the PAP. It reduces what eligible commercial-insurance patients pay at the pharmacy counter.

Eligibility:

• Commercial insurance that covers Wegovy at any tier.
• Wegovy is prescribed for chronic weight management (the FDA-approved indication for Wegovy).
• U.S. resident.
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded plan.

What it provides:

• Patients with insurance coverage of Wegovy may pay as little as $0 per 28-day supply for the first prescription, with continued reduced copays under the program rules.
• Maximum benefit caps apply, typically a few hundred dollars per fill.
• Limit on total fills covered per calendar year.

Where it falls short of free:

• If the plan's copay exceeds the maximum savings benefit, the patient pays the difference.
• If the deductible has not been met, the savings card may apply only after the patient pays a portion.
• If insurance does not cover Wegovy at all, the savings card cannot replace coverage. It only reduces a copay that already exists.

For commercially insured patients with Wegovy on formulary, the savings card can produce monthly out-of-pocket costs from $0 to $80, which is the closest most patients get to "free" without qualifying for the PAP.

Clinical trials with free GLP-1 medication

Active obesity and diabetes clinical trials sometimes provide free study medication, free study visits, and a participation stipend.

Where to search:

• ClinicalTrials.gov, the federal registry maintained by the National Library of Medicine.
• Filter for "obesity," "weight loss," "GLP-1," "semaglutide," or specific drug names.
• Filter by location and recruiting status.

Realistic expectations:

• Most obesity trials run 24 to 72 weeks.
• Some trials randomize participants to placebo, meaning a 33 to 50% chance of receiving inactive injection during the trial.
• Open-label extension phases (where everyone gets active drug) sometimes follow the randomized phase.
• Stipends typically run $25 to $100 per visit, with 8 to 16 visits over the trial.
• Eligibility criteria are strict. Common exclusions include type 1 diabetes, recent bariatric surgery, certain medications, and pregnancy.

A patient willing to commit to monthly clinic visits and tolerate possible placebo assignment can sometimes get free or stipended GLP-1 medication through a trial. The path is not fast, and most trials enroll only at major academic medical centers.

The NIH-funded SELECT, STEP, SURMOUNT, and SUSTAIN trial families have largely completed enrollment as of 2026, but follow-on trials and head-to-head comparisons continue to recruit (Lincoff et al., NEJM 2023).

State and nonprofit assistance programs

A few state-level and nonprofit programs can help with Wegovy costs, though most are designed for general prescription affordability rather than weight-loss medication specifically.

Examples:

• NeedyMeds.org. A nonprofit clearinghouse listing patient-assistance programs from manufacturers, government agencies, and charities.
• RxAssist.org. Similar to NeedyMeds, with a searchable database of free and low-cost medication programs.
• State pharmaceutical assistance programs. Some states (New York, Pennsylvania, New Jersey, Maryland, others) operate programs for residents who cannot afford prescriptions. Coverage of weight-loss medications varies.
• Hospital charity care. Many nonprofit hospitals run charity-care programs that include medication costs for patients meeting income thresholds.
• Disease-specific charities. The Obesity Action Coalition occasionally maintains funds or referrals.

These programs are usually a backup, not a primary source of free Wegovy. The PAP is faster and more reliable for income-qualified patients.

Why "free Wegovy" ads online are almost always scams

Search results and social-media ads promising "free Wegovy" or "Wegovy giveaways" almost always lead to one of three things:

1. Lead-generation traps. Sites collect personal and insurance information, then sell the data or use it to charge for unrelated products.
2. Counterfeit or unregulated drug schemes. A 2024 FDA warning detailed seizures of counterfeit semaglutide pens being sold online, some containing the wrong active ingredient and some containing no active ingredient (FDA Drug Safety Communication 2024).
3. Bait-and-switch consultations. "Free Wegovy" leads to a paid consult that ends in a non-Wegovy prescription, often a research-grade compound from an unverified source.

Real free Wegovy comes from one of the legitimate paths above (PAP, clinical trial, or savings card). It does not come from a sponsored social-media post or a quiz site.

Patients who suspect a counterfeit can verify a Wegovy pen by checking the lot number with Novo Nordisk's customer service line and inspecting the pen against the manufacturer's authenticity guide.

The compounded semaglutide alternative when free is not available

For patients who do not qualify for free Wegovy, compounded semaglutide is the most common low-cost alternative.

Pricing reality:

• FormBlends compounded semaglutide starts at $179 per month.
• Other major telehealth services range $199 to $499 per month.
• Local 503A compounding pharmacies often run $150 to $350 per month.

Why this is relevant to the "free Wegovy" question:

A patient with no insurance and no PAP eligibility looking at $1,300+ per month cash for Wegovy will often find that $179 per month for compounded semaglutide is functionally what "free" looks like for their situation. It is not zero, but it is the lowest legal price for ongoing GLP-1 therapy.

Important differences:

• Compounded semaglutide is not FDA-approved.
• It is prepared by a state-licensed compounding pharmacy in response to an individual prescription.
• It is drawn from a vial with a U-100 insulin syringe, not a pre-filled pen.
• It is not interchangeable with brand-name Wegovy.

The decision between paying for compounded semaglutide and pursuing the PAP path depends on income, insurance, and how quickly treatment is needed. The PAP path takes 5 to 10 business days. Compounded semaglutide can ship within 3 to 5 business days after the consult.

A 5-step plan to find your lowest-cost option

Step 1: Check insurance coverage of Wegovy. Call the number on the back of your insurance card. Ask whether Wegovy is on formulary, what tier, what the copay is, whether prior authorization is required, and whether the savings card is accepted.

Step 2: Apply for the savings card if commercially insured. Free to download from Novo Nordisk. No income requirement. Stack with insurance at the pharmacy counter. Most patients with commercial insurance and Wegovy coverage can get the cost down meaningfully.

Step 3: Apply for the PAP if uninsured and income-qualified. Roughly 5 to 10 business days for approval. Provider must complete medical-necessity portion. Income verification required. If approved, the medication is free.

Step 4: Search ClinicalTrials.gov for active trials. Use filters for location, drug class, and recruiting status. Realistic for patients near major medical centers and willing to commit to study schedules.

Step 5: If none of the above work, evaluate compounded semaglutide. Lowest legal monthly price for ongoing therapy when free Wegovy is not accessible. Available through licensed telehealth platforms with a real provider consultation.

FAQ

Can I get Wegovy for free? Yes, if you qualify for the Novo Nordisk Patient Assistance Program (income at or below 400% federal poverty level, no insurance coverage of Wegovy, U.S. resident, not on a government plan). Free Wegovy is also sometimes available through clinical trials.

Does Wegovy have a free trial offer? The Wegovy savings card sometimes provides a $0 or reduced cost first fill for newly enrolled commercially insured patients, then continues with reduced copays. Check the current offer terms on the official Novo Nordisk site.

How do I qualify for the Novo Nordisk Patient Assistance Program? Household income at or below 400% of the federal poverty level, no insurance coverage of Wegovy, U.S. resident, and a provider-signed medical-necessity statement. Application materials are on the NovoCare website.

Can Medicare patients get Wegovy for free? Manufacturer copay cards exclude Medicare patients by federal law. Some Medicare Extra Help programs reduce out-of-pocket costs but rarely to zero. Medicare Part D coverage of Wegovy expanded in 2025 for cardiovascular indications but is still narrow.

Does Medicaid pay for Wegovy? Coverage varies by state. Some state Medicaid programs cover Wegovy with prior authorization and BMI requirements. Others exclude weight-loss medications entirely. Check your state Medicaid formulary.

How long does the Patient Assistance Program approval take? Typically 5 to 10 business days after the completed application is received by Novo Nordisk. Faxed applications are processed faster than mailed in most cases.

Can I get Wegovy through a clinical trial? Yes, sometimes. ClinicalTrials.gov lists active trials. Be aware that randomized trials may assign you to placebo. Open-label extensions and post-marketing studies sometimes guarantee active medication.

Are "free Wegovy" offers on social media legitimate? Almost never. Most are lead-generation traps or counterfeit drug schemes. Real free Wegovy comes from the manufacturer's PAP or a registered clinical trial. The FDA has issued warnings about counterfeit semaglutide sold online.

Is compounded semaglutide ever free? No. Compounded medications are prepared by pharmacies in response to individual prescriptions and require payment. The lowest legal monthly cost for ongoing GLP-1 therapy is typically $150 to $250 per month for compounded semaglutide.

Can my doctor give me free Wegovy samples? Manufacturer samples of Wegovy are limited and intended for short-term initiation. Some clinics receive sample pens from Novo Nordisk reps. Availability varies by clinic and is not a sustainable source of free medication.

What is the difference between the savings card and the PAP? The savings card reduces copays for commercially insured patients to as little as $0 per fill, with caps. The PAP provides free Wegovy for income-qualified uninsured patients. They are separate programs with separate eligibility rules.

How long can I stay on the Patient Assistance Program? Approvals are typically valid for 12 months and renewable annually if you continue to meet the eligibility criteria. If you gain insurance coverage of Wegovy during the year, you transition off the PAP.

Sources

1. Novo Nordisk Patient Assistance Program (NovoCare PAP) eligibility documentation, accessed Q1 2026.
2. Novo Nordisk. Wegovy Savings Card Program Terms and Conditions. Accessed 2026.
3. U.S. Food and Drug Administration. FDA Drug Safety Communication: Counterfeit Ozempic and semaglutide warning. 2024.
4. ClinicalTrials.gov. Search results for active obesity and GLP-1 trials. Accessed Q1 2026.
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
7. Centers for Medicare & Medicaid Services. Medicare Part D Drug Coverage Determinations 2026.
8. NeedyMeds. Patient Assistance Program directory. Accessed 2026.
9. RxAssist. Free and low-cost medication program directory. Accessed 2026.
10. Obesity Action Coalition. Treatment Access and Insurance Coverage Resource. Accessed 2026.
11. Federal Trade Commission. Consumer Alert on counterfeit weight-loss drug scams online. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. NovoCare is a service mark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.